Effect of hormone receptors and Her-2 status on metastasis status in patients with breast cancer using logistic regression model
Authors
Abstract:
Introduction: Breast cancer is the most common type of cancer and the leading cause of cancer death among women. According to estimates in 2018, the most frequency of cancer in Iranian women was related to breast cancer with 13776 (12.5%) new cases. Metastasis is a complication of this disease that occurs in 1%-5% of patients. The aim of this study was to investigate the effect of hormone receptors and Her-2 status on metastasis status in patients with breast cancer using logistic regression. Materials and Methods: In this retrospective study, medical records of 165 breast cancer patients referred to the Ahvaz Shafa Diagnostic and Treatment Center who underwent surgery during 2006-2014 was recorded. Multinomial logistic regression model was applied to identify the related factors to the metastasis status. Results: In the studied patients, 35.2% (58 patients) experienced metastasis. In multinomial logistic model, Her-2 status (P = 0.026) and lymph node involvement (P <0.001) were significant. The odds of metastasis in ER-positive individuals was 2.24 times that of ER-negative individuals (AOR=2.24; CI95%: (0.955-5.275)). Also, the odds of metastasis in patients with lymph node involvement was 5.40 times that of patients without involvement (AOR=5.407; CI95%: (2.180-13.414)). This odds in people with Her-2-positive status was 2.35 times than in those with Her-2-negative status (AOR=0.438; CI95%: (1.109-4.999)). Conclusion: In this study, Her-2-positive status and lymph node involvement were identified as factors associated with metastasis. Early detection of these factors can lead to greater survival of breast cancer patients.
similar resources
Role of Cyclooxygenese-2 (COX-2) Expression in Breast Cancer Differentiation and Its Relationship with Hormone Receptors Status
Background and Objectives: Cyclooxygenese-2 (COX-2) expression in breast cancer and its correlation with tumor prognosis is unclear. We investigated the incidence of COX-2 expression in patients and assessed interactions between COX-2 and clinical features of cancer and expression of HER2/neu, estrogen receptor (ER), and progesterone receptor (PR). Methods: COX-2 expression was investigated by...
full textRelation between Estrogen and Progesterone Receptor Status with p53, Ki67 and Her-2 Markers in Patients with Breast Cancer
Background: Breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. Assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. The purpose of this study was to determine the relationship between estrogen and progesterone receptors with Her-2, Ki67, P53, and clinicopathologica...
full textinteraction between her-2 and hormone receptors in breast cancer
introduction: breast cancer is the most common malignancy with more than one million new cases diagnosed annually all around the world. its growth is mostly regulated by steroid hormones such as estrogen and peptide growth factors in interaction with epidermal growth factor 1 and 2. methods and materials: in this study, 237 patients who had consulted the oncology clinic of tabriz university of ...
full textrole of cyclooxygenese-2 (cox-2) expression in breast cancer differentiation and its relationship with hormone receptors status
background and objectives: cyclooxygenese-2 (cox-2) expression in breast cancer and its correlation with tumor prognosis is unclear. we investigated the incidence of cox-2 expression in patients and assessed interactions between cox-2 and clinical features of cancer and expression of her2/neu, estrogen receptor (er), and progesterone receptor (pr). methods: cox-2 expression was investigated by...
full textDetection of HER 2 Status in Breast Cancer : Comparison of
Breast cancer is responsible for 28% of the newly diagnosed cancer cases in women worldwide (Siegel et al., 2013). Iranian female breast cancer patients are affected at least 10 years earlier (average age of diagnosis, 47.1-48.8 years old) than those in Western countries (Babu et al., 2011). The treatment regimens for breast cancer patients are selected according to the biology and behavior of ...
full textMy Resources
Journal title
volume 23 issue 6
pages 748- 755
publication date 2021-11
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023